Compound’s yield-method model values Caris Life Sciences’ first-lien term loan at 101.36% of par, clean, at September 30, 2026. The two public BDCs that hold it, Blue Owl Capital Corp and Blue Owl Technology Finance Corp, both mark it at 100.00, up from 99.50 the quarter before. The model sits 1.36 points above each mark, inside the 3-point threshold the request set, and none of the three flags trips.
The value is above par because the model’s discount margin, 4.66% over forward SOFR, is below the loan’s 5.00% contractual spread. It gets there from a margin calibrated to the issue price, then lowered for tighter single-B spreads and for Caris’s lower leverage. Both adjustments rest on analyst assumptions, and the headline treats the loan as outstanding to its 2031 maturity. Repaid in April 2029, the model’s expected date, it is worth 100.83.
You are on the valuation team of a BDC or a private credit fund, or at the valuation agent that reviews its marks. For each Level 3 loan you need a value as a percent of par that ties to the loan’s terms, a market yield you can defend from the price at issue, and a note on each move since. We asked Compound to build that valuation on a real loan from public filings. It ran on November 19, 2026 and returned one Excel workbook of seven sheets and a short written answer.
What the workbook shows:
- The loan. The $400 million 2026 Term Loan closed on April 1, 2026 at Term SOFR + 5.00%. It has no amortization, pays interest quarterly and is due in full on April 1, 2031. The coupon in effect at September 30, 2026 is 8.7%.
- The holders. Blue Owl Capital Corp holds $19,714 thousand of par and Blue Owl Technology Finance Corp $28,929 thousand. Both carry the loan at cost of about 99.54 and fair value of 100.00.
- The calibration. An issue price of 99.503, backed out of Blue Owl’s cost, implies a discount margin of 5.138% over forward SOFR and an all-in yield of 9.11%.
- The adjustments. Half of a 0.45% tightening in single-B high-yield spreads takes 0.225% off the margin, and Caris’s credit metrics take off another 0.255%.
- The result. 101.36 to maturity, 100.83 to April 1, 2029, a 9.85% yield to maturity, and a sensitivity grid from 97.73 to 105.16.
The loan terms, the BDC holdings and Caris’s own fair value disclosure come from filings on SEC EDGAR: the Forms 10-Q of both BDCs and of Caris for the quarters ended June 30 and September 30, 2026, the 2026 Financing Agreement filed with Caris’s first-quarter 10-Q, and its fourth-quarter 2025 earnings release. Quarterly revenue, operating income, D&A and cash come from Compound’s company financial data. Coupons and discount rates use Compound’s SOFR forward curve at the March 31 and September 30 closes, fitted to SOFR swap trades and the New York Fed SOFR fixing. The single-B and all-ratings high-yield spreads come from FRED on the web. Every other input is marked as an analyst assumption with a reason.
“I need to mark a private loan at fair value under ASC 820 using the yield method, on a real loan. From the latest 10-Q schedules of investments of public BDCs, pick one first-lien term loan to a single borrower that two or more BDCs hold, with each BDC's spread, maturity, par, cost and fair value. Build the loan's cash flows to maturity from the SOFR forward curve, the contractual spread and floor, and its amortization. Calibrate the market yield at origination so the model reproduces the price the loan was issued at, then move that yield for the change since origination in leveraged loan or high-yield spreads and for the change in the borrower's own credit, such as leverage and coverage from its filings or the BDCs' disclosures, with a note on each adjustment. Discount the cash flows at the resulting yield to get fair value as a percent of par, and compare it with each BDC's mark and with the quarter before. Add the expected life, the yield to a three-year take-out, and a sensitivity table of fair value to the market yield and the expected repayment date. Flag a difference of more than two points between the BDCs' marks, a mark above par on a loan whose borrower's credit has weakened, and a model value more than three points from either mark. Use the stored public data wherever it has the figure, and web search only for what it lacks. Put every input on an Assumptions sheet with one column that says where it came from: a cited source, or "analyst assumption" for a figure I would set myself, with the reason for the value you chose. Every output must be a live formula that traces back to the Assumptions sheet. Add a Sources sheet listing each data source, what it gave and its date. Deliver one Excel workbook and a short summary of the result, the flags, and what I would need from the valuation agent to firm it up. Cite every sourced figure.”
That is the request as we sent it, without its closing line, which asks that no name or email be put in the workbook.
Choosing the loan and its two holders
Compound chose the Caris Life Sciences 2026 Term Loan, which both Blue Owl Capital Corp and Blue Owl Technology Finance Corp carry at S+5.00% maturing April 2031 in their September 30, 2026 schedules of investments. Each marks it at 100.00, half a point above its June 30 mark of 99.50. Caris’s own 10-Q puts the whole facility at 101.68.
| B | C | D | E | F | G | H | I | J | |
|---|---|---|---|---|---|---|---|---|---|
| 36 | Holder | Par, Sep 30 ($000) | Cost, Sep 30 ($000) | Fair value, Sep 30 ($000) | Mark, Sep 30 (% of par) | Cost (% of par) | Mark, Jun 30 (% of par) | Change in mark (pts) | Model less mark, Sep 30 (pts) |
| 37 | Blue Owl Capital Corp (OBDC) | 19,714 | 19,624 | 19,714 | 100.00 | 99.54 | 99.50 | 0.50 | 1.36 |
| 38 | Blue Owl Technology Finance Corp (OTF) | 28,929 | 28,797 | 28,929 | 100.00 | 99.54 | 99.50 | 0.50 | 1.36 |
| 39 | Combined Blue Owl position | 48,643 | 48,421 | 48,643 | 100.00 | 99.54 | 99.50 | 0.50 | 1.36 |
| 40 | Memo: borrower disclosure (whole $400m facility) | 400,000 | 406,700 | 101.68 | 102.00 | (0.32) | (0.31) |
The terms in the two schedules match the borrower’s own disclosure: Caris’s 10-Q for the quarter ended September 30, 2026, filed on November 4, 2026, describes a $400.0 million initial draw at Term SOFR plus 5.00%, interest-only, quarterly, with no scheduled principal and a maturity of April 1, 2031. A footnote in Blue Owl Capital Corp’s schedule puts the loan on 6-month SOFR. A $300 million delayed-draw facility sits beside the term loan and was undrawn at September 30, 2026.
Two features of the pair matter for the flags. Both holders are Blue Owl-managed BDCs, so the 0.00 gap between their marks says the manager marked one position consistently across two funds; it is not two independent views. And the borrower’s own Level 3 discounted cash flow figure, $406.7 million at September 30 and $408.0 million at June 30, is a third reference point the request did not ask for. Caris’s disclosed value fell 0.32 points in the quarter, while the lenders’ marks rose half a point.
The SOFR floor is redacted in the filed financing agreement. Compound assumed 0.75%, “typical for 2026 direct-lending loans,” and noted that it does not bind, since every forward on both curves is far above it.
Cash flows from the SOFR forward curve
The model projects the loan per 100 of par on Actual/360, with each 6-month reset set at the 6-month SOFR forward plus 5.00% and each quarter discounted at the 3-month forward plus the discount margin. The current period runs at the 8.7% coupon in effect, and principal comes back in one payment of 100 in April 2031.
| C | F | H | I | K | N | Q | R | S | |
|---|---|---|---|---|---|---|---|---|---|
| 27 | Payment date | Days | SOFR at reset | Coupon | Interest | Total cash flow | Discount SOFR (3M fwd) | Discount factor | PV |
| 28 | 9/30/2026 | 1.000000 | |||||||
| 29 | 10/1/2026 | 92 | 3.700% | 8.700% | 2.223 | 2.223 | 4.045% | 0.999758 | 2.223 |
| 30 | 1/1/2027 | 92 | 4.221% | 9.221% | 2.357 | 2.357 | 4.045% | 0.978008 | 2.305 |
| 31 | 4/1/2027 | 90 | 4.221% | 9.221% | 2.305 | 2.305 | 4.364% | 0.956435 | 2.205 |
| 32 | 7/1/2027 | 91 | 4.762% | 9.762% | 2.468 | 2.468 | 4.637% | 0.934480 | 2.306 |
| 33 | 10/1/2027 | 92 | 4.762% | 9.762% | 2.495 | 2.495 | 4.827% | 0.912364 | 2.276 |
| 34 | 1/1/2028 | 92 | 4.916% | 9.916% | 2.534 | 2.534 | 4.893% | 0.890626 | 2.257 |
| 47 | 4/1/2031 | 90 | 4.797% | 9.797% | 2.449 | 102.449 | 4.772% | 0.654778 | 67.082 |
The 8.7% coupon was in effect at both June 30 and September 30, which Compound reads as a 6-month SOFR period fixed on April 1 at about 3.7%. The model therefore holds the July-to-October period at 8.7% and starts the forward curve at the October 1, 2026 reset, where 6-month SOFR is 4.221%. The curve is steep at the front: the discount rate for the quarter from April 2027 is 4.637%, and the coupon set in April 2027 is 9.762%.
The payment calendar, quarterly on the first of January, April, July and October, is an analyst assumption that follows the April 1 closing. So is Actual/360, the market convention for Term SOFR loans. On those cash flows, the sum of the discounted payments to maturity is 103.562 per 100 of par, dirty, and 2.199 of that is interest accrued since July 1.
A second sheet, Orig_CF, runs the same build from the April 1, 2026 closing on the March 31 forward curve, where the first 6-month forward is 3.69%. That is the curve the calibration uses.
Calibrating the discount margin to the issue price
The calibration solves for the discount margin that makes the loan’s projected cash flows at closing worth exactly its issue price. With an issue price of 99.503, that margin is 5.138% over forward SOFR, 13.8 basis points above the coupon spread (our arithmetic), for an all-in yield at issue of 9.11%.
| B | C | |
|---|---|---|
| 7 | OBDC cost, % of par, prior quarter-end | 99.523 |
| 8 | OBDC cost, % of par, current quarter-end | 99.543 |
| 9 | OTF cost, % of par, prior quarter-end | 99.523 |
| 10 | OTF cost, % of par, current quarter-end | 99.544 |
| 11 | Average cost accretion over the quarter (pts) | 0.021 |
| 12 | Issue price implied by BDC cost (per 100) | 99.503 |
| 13 | Issue price implied by borrower net proceeds (per 100) | 98.375 |
| 14 | Issue price used for calibration | 99.503 |
| 15 | Trial discount margin 1 | 5.0000% |
| 16 | PV at trial 1 | 100.066 |
| 17 | Trial discount margin 2 | 6.0000% |
| 18 | PV at trial 2 | 96.081 |
| 19 | Trial discount margin 3 (secant step) | 5.1412% |
| 20 | PV at trial 3 | 99.491 |
| 21 | Calibrated discount margin at origination | 5.1383% |
| 22 | PV at calibrated margin | 99.503 |
| 23 | Check: PV less issue price | 0.000248 |
| 24 | All-in yield at issue (annual, XIRR) | 9.11% |
Calibration is what makes a yield-method mark defensible. A loan made at arm’s length is, on its funding date, worth what the lender paid for it, so the issue price is the one observation of the market yield for this exact credit, structure and documentation. Solving for the margin that reproduces that price ties the valuation to the transaction. From then on, the valuation date’s yield is the calibrated yield moved only for what has changed, and each move needs its own evidence. If nothing had changed, the model would carry the loan near its issue price, accreting toward par.
The issue price is not public. Compound took it from Blue Owl’s own books: both BDCs carried the loan at 99.523 at June 30 and about 99.543 at September 30, so cost accreted about 0.021 points in the quarter. Rolling the June cost back 90 days to the April 1 closing at that rate gives 99.503. The alternative, Caris’s $393.5 million of net proceeds, gives 98.375, but that figure includes all the lender fees the borrower reported, including any on the $300 million delayed-draw line, so Compound kept it as a switch on the Assumptions sheet and did not use it in the base case.
The solve itself is two secant steps written as worksheet formulas, so it stays live. At the contractual 5.00% the cash flows are worth 100.066; at 6.00%, 96.081. The first step lands at 5.1412% and 99.491; the second at 5.1383%, which prices the loan at 99.503, within 0.000248 points of the target. The XIRR of that price against the projected cash flows is 9.11%.
The 13.8 basis points above the spread (our arithmetic) is the original issue discount spread over the loan’s five-year life. Carrying it forward means the valuation starts from what the lenders accepted at issue, discount included, rather than from an assumption that the loan was priced at par.
Moving the yield for market spreads and Caris’s credit
From 5.138%, the model takes 0.225% off for half of the tightening in single-B high-yield spreads since March 31 and 0.255% for Caris’s lower leverage and higher coverage. The valuation margin is 4.658%, and the all-in yield 9.85%, higher than at issue only because forward SOFR has risen since April.
Discount margin over forward SOFR, from issue to valuation
Percent over forward SOFR. Calibrated at the April 1, 2026 closing; valued at September 30, 2026
Compound's Valuation tab, market yield build-up. Spreads: ICE BofA single-B US High Yield Index option-adjusted spread, via FRED.
| B | C | |
|---|---|---|
| 16 | Item | Value |
| 17 | Issue price used for calibration (per 100) | 99.503 |
| 18 | Discount margin at origination (calibrated) | 5.138% |
| 19 | All-in yield at issue (annual) | 9.11% |
| 20 | Change in single-B HY OAS since origination | (0.45%) |
| 21 | Pass-through to this loan | 50% |
| 22 | Market spread adjustment | (0.225%) |
| 23 | Borrower credit adjustment | (0.255%) |
| 24 | Discount margin at valuation | 4.658% |
| 25 | All-in market yield at valuation (annual, at model value) | 9.85% |
The market adjustment. The ICE BofA single-B US High Yield option-adjusted spread was 3.61% at the March 31 close before funding, 2.99% at June 30 and 3.16% at September 30, a 0.45% tightening since origination. Compound passed through half, an analyst assumption with its reason on the sheet: “direct-lending yields usually move less than public single-B spreads because the illiquidity premium is sticky.” The all-ratings high-yield index, carried as a memo, tightened less, from 3.28% to 3.12%.
The credit adjustment. The Credit sheet compares the four quarters to March 31, 2026, the last before closing, with the four quarters to September 30, 2026.
| B | C | D | E | |
|---|---|---|---|---|
| 16 | Metric | At origination | At valuation | Change |
| 17 | LTM revenue | 907.3 | 1,048.1 | 15.5% |
| 18 | LTM EBITDA ($M) | 129.0 | 162.4 | 33.5 |
| 20 | Term loan principal | 400.0 | 400.0 | 0.0 |
| 21 | Cash and short-term investments | 823.5 | 767.4 | (56.1) |
| 22 | Net debt (negative = net cash) | (423.5) | (367.4) | 56.1 |
| 23 | Gross leverage: principal / LTM EBITDA (x) | 3.10x | 2.46x | (0.64x) |
| 25 | Run-rate cash interest on the term loan | 34.8 | 34.8 | 0.0 |
| 26 | Interest coverage: LTM EBITDA / run-rate interest (x) | 3.71x | 4.67x | 0.96x |
| 27 | Memo: coverage on reported LTM interest expense (x) | 2.27x | 3.81x | 1.54x |
LTM revenue grew 15.5% to $1,048.1 million and LTM EBITDA, operating income plus D&A with no add-backs, rose from $129.0 million to $162.4 million. With the $400 million principal unchanged, gross leverage fell from 3.10x to 2.46x and coverage of run-rate term loan interest rose from 3.71x to 4.67x. Caris still held $767.4 million of cash and short-term investments, $367.4 million more than the loan.
| B | C | |
|---|---|---|
| 30 | Item | Value |
| 31 | Change in gross leverage (x) | (0.64x) |
| 32 | Yield change from leverage | (0.160%) |
| 33 | Change in interest coverage (x) | 0.96x |
| 34 | Yield change from coverage | (0.096%) |
| 35 | Credit adjustment before cap | (0.255%) |
| 36 | Credit adjustment applied | (0.255%) |
| 37 | Borrower credit since origination | Improved |
The rates that turn those changes into basis points are analyst assumptions: 25 basis points per turn of leverage, “direct-lending pricing grids typically step about 25 bp per turn,” and 10 basis points per turn of coverage, kept small “because coverage and leverage share the EBITDA driver.” The leverage change is worth 0.160% and the coverage change 0.096%. A cap of 0.75% either way limits the formula to “a one-notch-type move”; a larger change is left to the valuation agent’s judgment. Here the cap does not bind.
The coverage figure uses the run-rate coupon on the new loan, not reported interest expense, because the origination LTM includes the higher-cost 2023 term loan that the April 1 financing refinanced. On reported interest the improvement is larger, from 2.27x to 3.81x, and the model’s choice keeps the refinancing out of the credit adjustment.
Fair value against the BDC marks
Discounted at 4.658% over the September 30 forward curve, the loan’s cash flows to maturity are worth 101.36 clean. That is 1.36 points above both Blue Owl marks and 0.31 points below Caris’s own disclosure. All three flags come back clear.
| B | C | |
|---|---|---|
| 6 | Valuation date | 9/30/2026 |
| 7 | Discount margin at valuation | 4.658% |
| 8 | Accrued interest at valuation date | 2.199 |
| 9 | PV of cash flows to maturity (dirty) | 103.562 |
| 10 | Fair value to maturity, clean (% of par) | 101.363 |
| 11 | Three-year take-out date (first payment date on or after) | 10/1/2029 |
| 12 | Prepayment premium at take-out date | 0.0% |
| 13 | Expected repayment date (first payment date on or after) | 4/1/2029 |
| 14 | Prepayment premium at expected repayment date | 0.0% |
| 15 | PV of cash flows to expected repayment (dirty) | 103.027 |
| 16 | Value if repaid on expected repayment date, clean (% of par) | 100.827 |
| 17 | Combined BDC mark used for take-out yield (% of par) | 100.000 |
The arithmetic of the premium is simple. The loan pays 5.00% over SOFR and the model’s market margin is 4.658%, so a holder earns about 34 basis points a year above the market’s required spread (our arithmetic) on a bullet with 4.50 years to run. Discounted, that excess is worth 1.36 points. The rise in SOFR since April barely moves the price, because the coupon floats with the same curve the model discounts on.
| B | C | D | E | |
|---|---|---|---|---|
| 54 | Test | Value tested | Threshold | Result |
| 55 | Gap between BDC marks, Sep 30 (pts) | 0.00 | 2.0 | OK |
| 56 | OBDC mark above par while borrower credit weakened | 100.00 | 100.00 | OK |
| 57 | OTF mark above par while borrower credit weakened | 100.00 | 100.00 | OK |
| 58 | Model value vs OBDC mark (absolute pts) | 1.36 | 3.0 | OK |
| 59 | Model value vs OTF mark (absolute pts) | 1.36 | 3.0 | OK |
| 60 | Flags raised | 0 |
The request asked for a flag on a mark above par where the borrower’s credit has weakened. Neither condition holds: both marks are exactly 100.00, and the Credit sheet labels Caris’s credit “Improved.” The model’s own value is above par, but on the opposite combination, tighter spreads and better metrics, which is the case where a premium is expected. The model-versus-mark test, at 1.36 points against a 3-point threshold, is clear for both holders.
Compound’s answer also tests the inputs that move the result most:
| Change to the base case | Model value (% of par) |
|---|---|
| Base case | 101.36 |
| Issue price from Caris’s net proceeds (98.375) instead of Blue Owl cost | 100.33 |
| 100% pass-through of the single-B spread move | 102.20 |
| No pass-through of the spread move | 100.53 |
| No credit adjustment | 100.42 |
Every case stays above both marks. The issue price is the biggest lever: calibrating to the borrower’s net proceeds raises the starting margin and removes about a point (our arithmetic), which is why the fee letter tops the list of what to ask for.
Expected life and the three-year take-out yield
The loan has 4.50 years to maturity, but the model expects repayment on April 1, 2029, an expected life of 2.50 years. At the model value the yield to a three-year take-out on October 1, 2029 is 9.67%; bought at the 100.00 mark, it is 10.23%.
| B | C | |
|---|---|---|
| 43 | Item | Value |
| 44 | Weighted average life to maturity (years) | 4.50 |
| 45 | Expected repayment date | 4/1/2029 |
| 46 | Expected life to expected repayment (years) | 2.50 |
| 47 | Yield to maturity at model value (annual) | 9.85% |
| 48 | Three-year take-out date | 10/1/2029 |
| 49 | Yield to three-year take-out at model value (annual) | 9.67% |
| 50 | Yield to three-year take-out at the BDC mark (annual) | 10.23% |
| 51 | Yield to expected repayment at model value (annual) | 9.55% |
The expected repayment date is an analyst assumption, three years after closing. Compound’s reason: Caris is public, net cash and improving, and the assumed prepayment premium is gone after the second anniversary, so a refinancing before 2031 is likely. The premium itself, 2% in the first year and 1% in the second, is also assumed, because it is set in a lender fee letter that is not public; the borrower’s 10-Q confirms only that a timing-based premium exists.
The yields line up the way a premium price should. Paid 101.36, a holder repaid at par earns 9.85% to 2031, 9.67% to October 2029 and 9.55% to April 2029: the earlier the take-out, the less time to earn back the premium. A buyer at the 100.00 mark earns 10.23% to the same take-out, 56 basis points more than at the model value (our arithmetic), which is the yield cost of the 1.36-point difference over three years.
The sensitivity grid: market yield against repayment date
Across a 200 basis point range of discount margins and six repayment dates, the model value runs from 97.73 to 105.16. Each 25 basis points moves the value about 0.9 points if the loan runs to maturity and about 0.1 points if it is repaid in April 2027, where the 1% premium also props it up.
| B | C | D | E | F | G | H | I | |
|---|---|---|---|---|---|---|---|---|
| 6 | Repayment date | 4/1/2027 | 10/1/2027 | 4/1/2028 | 4/1/2029 | 4/1/2030 | 4/1/2031 | |
| 7 | Prepayment premium on that date | 1.0% | 1.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| 9 | Yield shift (bp) | Discount margin | ||||||
| 10 | (100) | 3.66% | 101.63 | 102.24 | 101.94 | 103.11 | 104.18 | 105.16 |
| 11 | (50) | 4.16% | 101.38 | 101.75 | 101.23 | 101.96 | 102.63 | 103.24 |
| 12 | (25) | 4.41% | 101.26 | 101.51 | 100.87 | 101.39 | 101.86 | 102.30 |
| 13 | 0 | 4.66% | 101.13 | 101.26 | 100.52 | 100.83 | 101.11 | 101.36 |
| 14 | 25 | 4.91% | 101.01 | 101.02 | 100.17 | 100.27 | 100.36 | 100.44 |
| 15 | 50 | 5.16% | 100.89 | 100.78 | 99.82 | 99.71 | 99.61 | 99.53 |
| 16 | 100 | 5.66% | 100.64 | 100.30 | 99.12 | 98.61 | 98.14 | 97.73 |
Model value by repayment date at three discount margins
Percent of par, clean, at September 30, 2026. Repayment at par plus the assumed premium due on that date
Compound's Sensitivity tab, rows 11, 13 and 15.
Two things stand out. The dip at April 2028 is the premium schedule: repayment in the first two years earns 1%, and from the second anniversary nothing, so a loan repaid in April 2028 loses its premium without the extra coupons a later repayment would bring. And at the base margin every cell is above par, from 100.52 to 101.36. The loan falls below par only when the margin rises by 50 basis points or more and the loan stays out to April 2028 or later.
The second grid on the sheet subtracts the 100.00 mark from each cell. The 3-point flag would trip in two corners: a margin 100 basis points lower with repayment in April 2029 or later, and a margin 50 basis points lower held to maturity, where the gap is 3.24 points. A margin 100 basis points higher takes the 2031 value 2.27 points below the mark.
What the public filings cannot tell you
The filings give the terms, the holders’ marks and the borrower’s results. The issue price, the premium, the floor and the comparable private loan prices sit with the lenders and the valuation agent. Compound’s answer lists what it would need from them, and each item replaces an assumption in the model.
- The lender fee letter. It sets the prepayment premium and shows how the fees split between the funded loan and the $300 million delayed-draw line. That split decides whether the issue price is nearer 99.503 or 98.375. The SOFR floor is redacted in the public filing too.
- Recent private first-lien prices for comparable healthcare credits. These replace the public single-B proxy and the 50% pass-through with direct evidence on how private yields have moved.
- The lender reporting package. Covenant-defined adjusted EBITDA and leverage replace the as-reported EBITDA in the credit adjustment. The only financial covenant disclosed is $50 million of minimum cash.
- Caris’s interest-period elections, to confirm 6-month SOFR resets from October 1.
- The agent’s view of when the loan will be repaid, which replaces the April 2029 assumption.
- The agent’s calibration memo, and the marks of the Blackstone-managed co-lenders, for a check across managers that the two Blue Owl funds cannot provide.
Our view
The build is the one we would start from: a calibrated margin, two adjustments each with a stated rate, and a grid that separates the yield question from the repayment question. Under its assumptions it says the loan is worth somewhat more than par. We would report the 100.83 to the expected repayment date beside the 101.36, and spend the diligence on the issue price and the premium.
The model value and the Blue Owl marks point the same way. The marks rose half a point in the quarter, Caris’s own disclosure sits above par, and the model, built from the issue price and public spreads, lands between them at 101.36. Every variant in Compound’s answer stays above 100. These are the model’s results under its assumptions, not a view on Caris’s credit or on how the BDCs set their marks.
The other side is that a premium on a prepayable loan is fragile. The headline assumes the borrower keeps paying 5.00% over SOFR to 2031 while the model says the market would lend at 4.66%. A borrower with net cash and falling leverage has every reason to refinance once the premium falls away, and at the expected repayment date the premium shrinks to 0.83 points. A mark at par, as both Blue Owl funds carry it, is within the grid’s range: a margin 25 basis points higher with repayment in April 2028 gives 100.17.
Three findings would change our view: a fee letter that puts the lender’s price nearer the 98.375 net proceeds figure, comparable private loan prices that have tightened less than half the public single-B move, and a repayment expected in the second year, when the premium is still 1%. From here the work is a BDC portfolio analysis of how each holder marks its other first-lien loans, and a credit agreement analysis of the financing agreement’s prepayment and covenant terms.
Caris first-lien loan yield method valuation (Excel)Compound’s workbook from this run: the Valuation summary with the marks and the flags, the sensitivity grid, an Assumptions sheet with a source or reason beside every input, the borrower Credit metrics, the origination calibration, the valuation cash flows and Sources.Download · FreeFAQ
How is a private loan valued with the yield method under ASC 820?
Project the loan’s cash flows from its terms and the forward curve, then discount them at a market yield for a comparable loan on the valuation date. The yield starts from the one calibrated to the issue price and moves for changes in market spreads and the borrower’s credit. Here that gives a 4.658% margin over forward SOFR and a value of 101.36% of par.
What does calibration to the issue price mean in a loan valuation?
It means solving for the discount margin that makes the projected cash flows worth the price the lender paid at closing, so the valuation starts from an observed transaction. Caris’s loan, issued at about 99.503, calibrates to 5.138% over forward SOFR, above the 5.00% coupon spread because of the discount. Later marks move that margin only for documented changes.
Why would a yield-method value be above par on a floating-rate loan?
Because the market margin has fallen below the contractual spread. A floating coupon offsets moves in SOFR itself, so only the spread matters: here the loan pays 5.00% over SOFR against a 4.66% market margin, worth 1.36 points over 4.50 years. An earlier expected repayment shrinks the premium, to 0.83 points if the loan is repaid in April 2029.
How much of a public high-yield spread move should pass through to a private loan?
It is an analyst judgment that the valuation agent should test against private loan prices. This model passes through half of the 0.45% tightening in single-B spreads, because illiquidity premiums on direct loans tend to be sticky. Passing through all of it gives 102.20 and none of it 100.53, so the choice is worth about 1.7 points.
Should a loan mark use expected life or contractual maturity?
ASC 820 asks what a market participant would pay, and a buyer prices in the likely repayment. This model reports both: 101.36 to the 2031 maturity and 100.83 to an expected April 2029 repayment, with the sensitivity grid showing six repayment dates. The expected life is 2.50 years against 4.50 to maturity.





